Others have tried and failed to target α-synuclein in Parkinson’s disease, but Roche hopes a Phase II study could deliver success later this year.

The well-known businessman and TV personality told the White House that the US needs to ‘stop doing business with the big three PBMs,’ helping to fight the drug industry’s battle against the middlemen with a friendlier face not associated directly with the brand industry.

Argenx has aggressive market expansion plans for Vyvgart. It also has several late-stage challengers in what is becoming a dynamic market.

Friedreich’s ataxia is particularly prevalent in Europe, and the company hopes to replicate the fast US uptake for Skyclarys there.